H.C. Wainwright Reiterates a Buy Rating on Kadmon Holdings (KDMN)


In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kadmon Holdings (KDMN), with a price target of $25. The company’s shares closed yesterday at $2.85.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.5% and a 48.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Kadmon Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $14.50, a 408.8% upside from current levels. In a report issued on February 26, Citigroup also upgraded the stock to Buy with a $4 price target.

See today’s analyst top recommended stocks >>

Based on Kadmon Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $41.52 million. In comparison, last year the company had a GAAP net loss of $18.19 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts